UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Combination Antibiogram Evaluation for Pseudomonas aeruginosa in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals

Antimicrobial agents and chemotherapy, 2019-04, Vol.63 (4)

2019

Volltextzugriff (PDF)

Colistin Dosing and Nephrotoxicity in a Large Community Teaching Hospital

Antimicrobial Agents and Chemotherapy, 2010-10, Vol.54 (10), p.4503-4505

2010

Volltextzugriff (PDF)

Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study

Open forum infectious diseases, 2018-10, Vol.5 (10), p.ofy241-ofy241

2018

Volltextzugriff (PDF)

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020

BMC microbiology, 2023-06, Vol.23 (1), p.165-12, Article 165

2023

Volltextzugriff (PDF)

Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa – Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020

International journal of infectious diseases, 2022-12, Vol.125, p.250-257

2022

Volltextzugriff (PDF)

Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018

International journal of infectious diseases, 2021-11, Vol.112, p.321-326

2021

Volltextzugriff (PDF)

Antimicrobial stewardship and antibiograms: importance of moving beyond traditional antibiograms

Therapeutic Advances in Infectious Disease, 2021, Vol.8

2021

Volltextzugriff (PDF)

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020

The Brazilian journal of infectious diseases, 2023-05, Vol.27 (3), p.102775-102775, Article 102775

2023

Volltextzugriff (PDF)

Response to Surawicz et al

The American journal of gastroenterology, 2014-10, Vol.109 (10), p.1684-1684

2014

Volltextzugriff (PDF)

Performance of a vancomycin dosage regimen developed for obese patients

American journal of health-system pharmacy, 2012-06, Vol.69 (11), p.944-950

2012

Volltextzugriff (PDF)

In vitro activity of ceftolozane/tazobactam against Gram‐negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries—SMART 2017–2019

Journal of global antimicrobial resistance., 2022-06, Vol.29, p.527-533

2022

Volltextzugriff (PDF)

Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United States

Antibiotics (Basel), 2022-05, Vol.11 (5), p.660

2022

Volltextzugriff (PDF)

Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence

Future microbiology, 2024, Vol.19 (6), p.465-480

2024

Volltextzugriff (PDF)

Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017–2020

Journal of global antimicrobial resistance., 2023-06, Vol.33, p.260-266

2023

Volltextzugriff (PDF)

Epidemiology, Treatment, and Outcomes of Nosocomial Bacteremic Staphylococcus aureus Pneumonia

Chest, 2005-09, Vol.128 (3), p.1414-1422

2005

Volltextzugriff (PDF)

Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019

International journal of antimicrobial agents, 2022-03, Vol.59 (3), p.106535-106535, Article 106535

2022

Volltextzugriff (PDF)

Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model

Antimicrobial Agents and Chemotherapy, 2007-04, Vol.51 (4), p.1481-1486

2007

Volltextzugriff (PDF)

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles : Impact on the development of resistance

Drugs (New York, N.Y.), 2006, Vol.66 (1), p.1-14

2006

Volltextzugriff (PDF)

In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020

Antimicrobial agents and chemotherapy, 2022-05, Vol.66 (5), p.e0018922

2022

Volltextzugriff (PDF)

Serum Bactericidal Activities of High-Dose Daptomycin with and without Coadministration of Gentamicin against Isolates of Staphylococcus aureus and Enterococcus species

Antimicrobial Agents and Chemotherapy, 2006-11, Vol.50 (11), p.3529-3534

2006

Volltextzugriff (PDF)

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020

International journal of antimicrobial agents, 2023-09, Vol.62 (3), p.106900-106900, Article 106900

2023

Volltextzugriff (PDF)

In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020

International journal of antimicrobial agents, 2023-05, Vol.61 (5), p.106772-106772, Article 106772

2023

Volltextzugriff (PDF)

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy—SMART 2017–2021

European journal of clinical microbiology & infectious diseases, 2024-07, Vol.43 (7), p.1343-1348

2024

Volltextzugriff (PDF)

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non- Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020

Journal of medical microbiology, 2023-02, Vol.72 (2)

2023

Volltextzugriff (PDF)

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020

European journal of clinical microbiology & infectious diseases, 2023-03, Vol.42 (3), p.365-370

2023

Volltextzugriff (PDF)

1 – 25 von 73

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(72)
Mit Volltextzugriff
(67)

Publikationsform

Artikel
(73)

Sprache

Englisch
(73)

Erscheinungsjahr

n.n

Thema

Science & Technology
(45)
Life Sciences & Biomedicine
(44)
Pharmacology & Pharmacy
(29)
Microbiology
(28)
Infectious Diseases
(27)
Humans
(25)
Pseudomonas Aeruginosa
(16)
Microbial Sensitivity Tests
(15)
Anti-Bacterial Agents - Pharmacology
(14)
Anti-Bacterial Agents - Therapeutic Use
(12)
Smart
(12)
Surveillance
(10)
Biological And Medical Sciences
(9)
Original
(9)
Poster Abstracts
(9)
Female
(8)
Medical Sciences
(8)
Ceftolozane/tazobactam
(7)
Male
(7)
Middle Aged
(7)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Combination Antibiogram Evaluation for Pseudomonas aeruginosa in Respiratory and Blood Sources from Intensive Care Unit (ICU) and Non-ICU Settings in U.S. Hospitals

Colistin Dosing and Nephrotoxicity in a Large Community Teaching Hospital

Carbapenem-Nonsusceptible Gram-Negative Pathogens in ICU and Non-ICU Settings in US Hospitals in 2017: A Multicenter Study

Relebactam restores susceptibility of resistant Pseudomonas aeruginosa and Enterobacterales and enhances imipenem activity against chromosomal AmpC-producing species: analysis of global SMART 2018-2020

Activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa from patients in the Middle East and Africa – Study for Monitoring Antimicrobial Resistance Trends (SMART) 2017-2020

Ceftolozane-tazobactam activity against clinical isolates of Pseudomonas aeruginosa from ICU patients with pneumonia: United States, 2015–2018

Antimicrobial stewardship and antibiograms: importance of moving beyond traditional antibiograms

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in Latin America: SMART 2018‒2020

Response to Surawicz et al

Performance of a vancomycin dosage regimen developed for obese patients

In vitro activity of ceftolozane/tazobactam against Gram‐negative isolates collected from ICU patients with lower respiratory tract infections in seven Asian countries—SMART 2017–2019

Use of Novel Antibiograms to Determine the Need for Earlier Susceptibility Testing and Administration for New β-Lactam/β-Lactamase Inhibitors in the United States

Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence

Carbapenem resistance among Gram-negative isolates collected from patients in ICU and non-ICU hospital wards in Hong Kong: SMART 2017–2020

Epidemiology, Treatment, and Outcomes of Nosocomial Bacteremic Staphylococcus aureus Pneumonia

Prevalence of ESBL non-CRE Escherichia coli and Klebsiella pneumoniae among clinical isolates collected by the SMART global surveillance programme from 2015 to 2019

Bactericidal Activities of Meropenem and Ertapenem against Extended-Spectrum-β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae in a Neutropenic Mouse Thigh Model

Optimising dosing strategies of antibacterials utilising pharmacodynamic principles : Impact on the development of resistance

In Vitro Activity of Ceftolozane-Tazobactam, Imipenem-Relebactam, Ceftazidime-Avibactam, and Comparators against Pseudomonas aeruginosa Isolates Collected in United States Hospitals According to Results from the SMART Surveillance Program, 2018 to 2020

Serum Bactericidal Activities of High-Dose Daptomycin with and without Coadministration of Gentamicin against Isolates of Staphylococcus aureus and Enterococcus species

In vitro activity of imipenem/relebactam against non-Morganellaceae Enterobacterales and Pseudomonas aeruginosa in the Asia-Pacific region: SMART 2017-2020

In vitro activity of ceftolozane/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017-2020

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical isolates of Enterobacterales and Pseudomonas aeruginosa collected in Greece and Italy—SMART 2017–2021

In vitro activity of imipenem/relebactam against piperacillin/tazobactam-resistant and meropenem-resistant non- Morganellaceae Enterobacterales and Pseudomonas aeruginosa collected from patients with bloodstream, intra-abdominal and urinary tract infections in Western Europe: SMART 2018-2020

Activity of ceftolozane/tazobactam and imipenem/relebactam against clinical gram-negative isolates from Czech Republic, Hungary, and Poland—SMART 2017–2020

Suchergebnisse filtern